10xBio Announces the Completion of Enrollment In Phase 2b Clinical Trial of Novel Drug For Submental Body Contouring

10xBio, LLC, a biotechnology company that focuses on new uses for existing therapies and technologies, announced today that it has completed enrollment in a repeat treatment study of its novel injectable drug for submental body contouring. The drug, 10XB101, is a proprietary formulation of polidocanol, which is approved in the U.S. for vein sclerotherapy. 10xBio is repurposing polidocanol for body contouring applications in aesthetic medicine.

The global non-invasive fat removal market is estimated at $4BB, and is currently dominated by medical devices and just one U.S. marketed drug containing deoxycholate as the active pharmaceutical ingredient. 10XB101 is an innovative alternative, with the potential to offer benefits including enhanced patient tolerability, shorter treatment intervals and more.

“I have been involved in the study of polidocanol for vein sclerotherapy for more than 40 years and am proud to lead the scientific and clinical effort to study this novel formulation of it for a new indication,” said Mitchel P. Goldman, M.D., a dermatologic surgeon and medical director of Platinum and West Dermatology. “I believe that 10XB101 can achieve superior efficacy and tolerability than the currently marketed body contouring drug, deoxycholate, which I have more than 10 years of experience with. I look forward to seeing the results of this trial.”

A total of 51 patients are enrolled in this randomized, double-blind study across three treatment groups, including a placebo control group. Patients will receive multiple injections of 10XB101 in a predefined pattern, and can receive multiple treatments spaced one month apart. Efficacy will be assessed with a physician and patient submental fullness rating scale, measured 12 weeks after the patient’s final treatment. Tolerability will be assessed by recording local skin reactions on a four-point ordinal scale, including edema/swelling, pain, bruising, tenderness on palpation and erythema. The study is expected to be completed by the end of 2023.

In a previous study, 10XB101 showed excellent tolerability with minimal pain, swelling, bruising and erytherma. Patients and physicians reported improvements in a submental fullness rating scale after a single treatment.

Source10xBio

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.